Abstract Central nervous system (CNS) tumors are categorized and graded for clinical and research purposes according to the World Health Organization (WHO) scheme which segregates tumors by histological type and predicted biological behavior. However, reporting of WHO grade in pathological reports is inconsistent despite its collection in cancer registration. We studied the com- 
Introduction
There are over 100 histologically distinct types of primary central nervous system (CNS) tumors, each with its own spectrum of clinical presentations, treatments, and outcomes. The first edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System was published in 1979 as a unifying system for classifying CNS tumors [1] . It has been revised three times, [2] [3] [4] , and has become the international standard for the categorization of CNS tumors. The WHO classification system acts as a common language for communication between clinical and basic science investigators worldwide [5] [6] [7] . Unlike most other cancers, CNS neoplasms are not staged and, therefore, grading takes on a heightened importance for patient management [8] . Grading assignment is achieved through the WHO classification system which provides a grading scheme in order to indicate predicted clinical behavior based on morphologic features (WHO grade I-IV) [5, 7] . As such, the WHO grade often estimates clinical outcomes and guides the management of some CNS tumors [5, 6] . Updates to WHO classification and grading result in improved correlations between histological grade and outcomes and can affect changes in diagnostic and clinical practice [7, 9] . WHO grading is also used in population and epidemiological studies to identify patterns of diagnosis for CNS tumors. For example, a substantial change from the 1993 to 2000 WHO classification and grading scheme for meningiomas resulted in an increase in the frequency of diagnosis and thus the incidence of grade II meningiomas, a tumor which carries a poorer prognosis than grade I meningiomas [10] .
However, despite its clinical and epidemiological use, reporting of WHO grade remains optional in both pathology reports and cancer registration [5, 6] . The College of American Pathologists (CAP) recommends, but does not require, that WHO grade be assigned in pathological reports [8] . Grading is also not a required item by either of the two major cancer registry programs in the United States: the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) and the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) program.
A previous study by Kruchko, et al. analyzed the completeness and concordancy of WHO grading for primary CNS tumor cases from 2004 to 2008 within 18 SEER cancer registries and revealed a substantial frequency of undocumented or discordant WHO grades [11] . The objective of this report is to expand and update this analysis by describing the completeness, concordancy and trends in the collection of WHO grade for primary CNS tumor cases from 2004 to 2011 using SEER data.
Materials and methods

Data collection
This study used data from the SEER program of the NCI, which includes *28 % of cancer cases for the US population [12] . Specifically, the SEER 18 Registries [16] . Information from the pathology report is first recorded by tumor registrars from treatment centers and cancer care programs who then send this information to central (state) cancer registries who submit it to SEER [17] . Tumor registrars and central cancer registries are held under quality controls checks to ensure that the information reported to SEER is as accurate and complete as possible.
Primary CNS tumors were identified for WHO grade analysis based on the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) site codes (C70.0-72.9, C75.1-75.3) [15] . CNS tumor groups were selected based on their overall incidence over the time period and by clinical interest [11] and listed according to ICD-O-3 histology and behavior codes (Table 2) . Since the histology and grade of CNS tumors are more accurately determined when they are microscopically confirmed, this study primarily focused on cases with microscopic (e.g. histopathologic) confirmation [17, 18] . Cases in which the histological diagnosis is assigned without microscopic confirmation, such as those identified radiographically without surgical resection and which are also reported to cancer registries, were included but not the focus of this study. Designated WHO grades for specific histological types were based on the 2007 WHO grading scheme [5] and did not differ substantially from the 2000 grading scheme for these selected histologies [7] . 
Results
Overall WHO Grade completeness and concordancy
Completeness and concordancy of WHO grade were calculated for all selected histologies as a group (Table 1) . From 2004 to 2011 there were a total of 86,080 cases, of which 57,480 (66.8 %) were microscopically confirmed and 28,600 that were not (33.2 %). Among all tumor cases, 39.7 % had documented WHO grade, and 93.6 % of those with documented WHO grade were graded concordantly.
Among microscopically confirmed cases, 58.5 % had documented WHO grade, and 93.6 % of these cases with documented WHO grade were graded concordantly. Cases that were not microscopically confirmed had 1.9 % of cases with documented WHO grade of which 95.9 % of these cases were graded concordantly. These included cases where the histological diagnosis was done radiographically, and a WHO grade was still recorded in the SEER registry. However, these cases were not further analyzed in regards to specific histologies or trends.
Histology-Specific WHO Grade completeness and concordancy
Selected histologic groups were analyzed individually for completeness and concordancy in WHO grade from 2004 to 2011 (Table 2 ). The percentage of microscopically confirmed tumor cases ranged from a low of 46.0 % for non-malignant meningioma to 100.0 % for anaplastic ependymoma.
Completeness of WHO grade varied by histological type. More than 80 % of all cases had grade documented for anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, and oligoastrocytoma/anaplastic oligoastrocytoma, whereas less than 25 % of all cases had WHO grade documented for craniopharyngioma and hemangioblastoma.
Concordancy of WHO grade also varied based on histological type. Among cases that were graded, more than 98 % of craniopharyngioma and hemangioblastoma were graded concordantly in contrast to anaplastic/malignant meningioma in which only 55.8 % were graded concordantly. Table 3 .
Discussion
A significant number of CNS tumor cases reported to SEER registries from 2004 to 2011 had undocumented WHO grade; however, among cases that were graded, over Table 2 ). The inclusion of WHO grade on pathology reports remains optional in the United States [5, 6] . Although clinicians are using WHO grading in their practices, WHO grade may not be documented on pathological reports. Furthermore, according to the College of American Pathology (CAP) guidelines, neuropathologists have options in reporting-including: choosing to assign a WHO grade, reporting grade as not applicable, reporting grade as cannot be determined, or not assigning a WHO grade-that may affect documentation and, therefore, further impede the registrar's ability to consistently collect this variable [8] .
Although the WHO Classification of Tumours of the Central Nervous System establishes a defined WHO grade for each histological diagnosis, neuropathologists make the final assignment of grades on a case by case basis [8] further complicating the documentation process. As a result, pathologists may choose to assign a WHO grade that deviates from the grading scheme (SEER registries record WHO grades based on the assignment of the working pathologist even if it deviates from the defined grading scheme [15] ). Tumors with deviated WHO grade would, therefore, contribute to the number of cases determined to be discordantly graded. However, we found that, overall, most diagnosed tumors conform to the WHO grading scheme and so these cases probably only account for a small proportion [5] . Finally, one cannot dismiss that errors in cancer registration are also a possible cause for both undocumented and discordant WHO grades. For example, if a pathologist assigns a concordant WHO grade on a pathology report, recording of grade in the registries could have been overlooked or recorded erroneously resulting in a tumor case with an undocumented or discordant WHO grade within the SEER database.
Only a small portion of all CNS tumor cases between 2004 and 2011 were discordantly graded, as most were either undocumented or assigned the concordant WHO grade (Tables 1, 2) . In other words, the large majority of these cases either had no documented WHO grade or were graded concordantly. This may indicate that neuropathologists are more likely to leave a WHO grade unassigned in a pathology report than assign a discordant WHO grade as it may be difficult to assign grade for tumors with histological features that are problematic to interpret or do not readily fit into a definitive grade [19] .
Microscopically confirmed cases had a higher proportion of documented WHO grade when compared to cases that were not microscopically confirmed ( Table 1 ). Cases that were not microscopically confirmed (e.g. CNS tumors identified radiographically but did not result in surgery for histologic confirmation) had WHO grade documented in 1.9 % of the cases. This finding most likely reflects the current practice in which WHO grade cannot be assigned for tumors that are diagnosed radiographically. Furthermore, many non-malignant CNS tumors may not receive surgery as their first course of treatment prohibiting microscopic (i.e. histopathologic) confirmation of their disease. These results reaffirm that microscopic confirmation is necessary for the assignment of histological type and grade for CNS tumors [17, 18] .
Overall, from 2004 to 2011 an increasing proportion of cases each year were documented and assigned with the concordant WHO grade (Fig. 1) . A factor which most likely contributed to the increase of documented and concordant WHO grade over time was the impetus in cancer centers to use a standardized protocol provided by the CAP in reporting the results of surgically biopsied or resected CNS tumors. This protocol was developed to assist pathologists in reporting useful and relevant information and consists of a checklist that specifies factors such as primary tumor site, histological diagnosis, and WHO grade [8] . WHO grade has been included in this protocol since its early versions before 2004 and the current version published in 2014 also includes the most updated WHO grading scheme as a reference for working pathologists. The rise in documented WHO grade may in part be explained by the mandate in programs seeking CoC accreditation to use the CAP protocol in pathology reports. Time trends for specific histologies such as glioblastoma and non-malignant meningioma show that improvements over time in completeness and concordancy of WHO grade vary significantly based on histology (Fig. 2) . Of particular note is the significant increase in the percentage of cases with documented WHO grades for grade I, II, and III meningiomas. This may reflect the changes in the 2000 WHO classification system in which the diagnosis of these tumors is correlated directly with grade and, therefore, contribute to making WHO grade documentation straightforward and reproducible [20] . Furthermore, these changes have helped clarify the determination of grade for the histological subtypes of meningioma, such as microcystic (grade I), chordoid (grade II), and papillary (grade III) meningiomas.
Variable trends in non-malignant meningioma (grade I), atypical meningioma (grade II), and anaplastic/malignant meningioma (grade III) most likely reflect changes in the diagnostic approach or classification of these tumors. The significant decrease in the percentage of cases with microscopic confirmation for non-malignant meningioma, the most common among the three types, may be the result of increased dependence or reliability on neuroimaging as the method of diagnosis for these tumors. Given that non-malignant meningioma accounts for an overwhelming majority of CNS tumor cases (Table 2) , a decrease in the percentage of non-malignant meningiomas with microscopic confirmation would cause a significant decrease in the overall percentage of microscopically confirmed cases seen in CNS tumors over the years (Fig. 1) . Yearly variability in the percentage of cases with concordant grading for atypical and anaplastic/malignant meningioma most likely reflects the continuing difficulty in establishing a system that consistently and appropriately classifies and grades these tumors. Multiple studies have shown that reassessment of meningiomas based on updated WHO classification and grading criteria have led to the reclassification of histological diagnosis and grade for these tumors. For instance, a study in 2006 by Simon, et al. studied the impact of the revised WHO 2000 classification system by analyzing 57 cases of meningioma that were previously classified and graded based on the WHO 1993 criteria [21] . They found that a significant number of cases previously diagnosed as atypical and anaplastic/malignant meningioma were classified and graded differently based on the WHO 2000 criteria in which the study suggested that more stringent criteria be established in the classification and grading of these tumors. A similar study by Yang, et al. in 2007 revealed parallel results [22] and another by Rosenberg, et al. in 2009 stated that the WHO 2000 and 2007 definitions for grade III meningiomas classify a substantially different group of tumors when compared to previous definitions [23] . Difficulty in the classification and grading of meningiomas will continue to produce variations in the diagnosis, grading, and epidemiology of these tumors.
Differences in diagnostic, prognostic, or therapeutic approach may influence the application of WHO grade for individual histologies and account for the variability seen in WHO grade assignment (Table 2 ). For instance, WHO grade can be a consistent predictor of clinical outcomes for some but not all tumors. For certain tumors, other characteristics such as molecular markers may be better at predicting clinical outcomes and guiding management [19] . Tumors with a higher percentage of documented WHO grade most likely represent histologies in which grade has been found to be clinically useful for prognosis and therapeutic management. Additionally, for histologies with similar or overlapping names, WHO grade may be more frequently assigned because it can act as a safety check to insure that the appropriate histological diagnosis was made. For instance, the assignment of WHO grade II for oligodendroglioma on a pathology report would help differentiate it from anaplastic oligodendroglioma which is assigned a WHO grade III. For histologies in which the name is distinct and only a single WHO grade is assigned, such as craniopharyngioma, the grade is implied in pathology report diagnosis and so the assignment of WHO grade might be considered redundant in the clinical setting and thus grade would be less often documented. Continued investigations in identifying patterns of completeness and concordancy in documentation of WHO grade would be useful in further understanding its clinical use and in determining if certain CNS tumors warrant reassignment of grade or classification.
Overall, improvements in completeness and concordancy of WHO grading are being seen overtime and efforts to continue this trend should be made. Pathologists should continue to use standardized protocols such as those offered by the CAP to ensure more consistent collection of this variable. Programs such as the CoC that accredits cancer care programs and cancer registries should also set high standards for the collection of grade and other cancer related elements, such as newer molecular markers, as these will be important in epidemiological and research studies. Updates to the WHO classification and grading system that adapt to the growing body of knowledge revolving around CNS tumors are essential, as this system has become the standard by which the neuro-oncology community diagnoses and grades tumors. By ensuring that grade accurately reflects tumor behavior and prognosis, clinicians will be more inclined to use it in their practices as a reliable indicator of patient outcomes, and thereby affecting its inclusion in the medical record and eventual collection by tumor registrars.
Strengths and limitations
This analysis provides important information on the use of WHO grade in clinical practice and the concordancy of its collection in a population-based cancer registry representing *28 % of brain and CNS tumor cases in the United States in a selected time period, 2004-2011.
An important limitation of this study is that, although quality control checks exist for cancer registries [17] , there is no mechanism for central pathology review. Trained cancer registrars abstract information on WHO grade directly from pathology reports which represent the opinions of individual pathologists and may influence the number of cases with concordantly/discordantly assigned WHO grade in spite of our focus on microscopically confirmed cases.
Similarly, the lack of central pathology review implies that there is uncertainty in whether an error in the assignment of WHO grade versus the histological diagnosis was made in cases in which the grade was discordant for the given histology. In this study, the histological diagnosis assigned by the pathologist was assumed to be accurate in which concordancy of WHO grade was subsequently determined. Implementation of a central pathology review system at the level of individual treatment centers and their registrars, central cancer registries, and with SEER would encourage complete, accurate, and reliable collection of WHO grade along with other useful and relevant cancer elements such as histological diagnosis and molecular markers.
Based on current guidelines, WHO grade and histological diagnosis ideally should have been directly recorded from pathology reports. However, this may not always be the case and the SEER*Stat statistical program used for this analysis is unable to verify if recorded WHO grades or histological diagnoses were in fact directly abstracted from pathology reports. Thus, any errors in the recording of WHO grade or histology that would be present in the SEER database would also be present in this analysis. Microscopically confirmed cases were chosen to be analyzed because SEER guidelines place priority in using pathological reports to record the histological diagnosis and WHO grade for these cases.
The inability to identify the cause on why certain cases were recorded with an undocumented WHO grade within the SEER registry was also a limitation of this study. It would be interesting to explore these cases to determine if WHO grades are primarily undocumented within registries because they are not being assigned by pathologists or because of errors in cancer registration. Determining these patterns would help identify areas of improvement and strategies for the collection of WHO grade. A special study looking at individual records would be needed in order to investigate the collection of WHO grade from clinical records in order to provide a clear evaluation of collection practices.
Conclusions
This study revealed that overall, primary CNS tumors reported to central cancer registries have a significant proportion of cases with undocumented WHO grade. For those cases with microscopic confirmation, even though discordant WHO grades were low, improvements in both the completeness and concordancy of WHO grading have been made over time. Neuropathologists and cancer registrars should continue their efforts to ensure that documentation of WHO grade is complete and concordant. The collection of this variable is important for cancer surveillance efforts and for performing a population-based calculation of clinical outcomes, as well as for clinical care and research purposes [20] [21] [22] [23] .
For clinicians and neuropathologists, assigning WHO grade holds significant clinical value for patient care in neuro-oncology. This is the case even in the context of testing for molecular markers which have currently been identified for several histologic types of CNS tumors and which will likely be used in combination with WHO grade to assign diagnosis and therapy, and to predict prognosis [6, 8, 19] . Along with histological identification, WHO grade will continue to provide important information for the prognosis and management of CNS tumors. For cancer surveillance, it is important that the collection of WHO grade continues to improve over time. Comprehensive and consistent inclusion of this variable in cancer databases helps to increase the clinical utility of cancer surveillance for population and epidemiological studies. Gaining a better understanding of trends of WHO grade collection in population-based registries may also prove useful in evaluating its application in clinical practices in the United States. Furthermore, this study provides documentation which may be useful to revisions of future grading schemes of the WHO Classification of Tumours of the Central Nervous System so that improved correlations between histological grade and outcomes continue to be made.
